Cargando…
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme
Glioblastoma is an aggressive tumor with poor survival rates. Bispecific T cell engagers (BTEs) against different cancers are in various stages of clinical development. Toxicity resulting from cytokine release syndrome and the short half-life of BTEs, which necessitates continuous infusion, complica...
Autores principales: | Bhojnagarwala, Pratik S., O’Connell, Ryan P., Park, Daniel, Liaw, Kevin, Ali, Ali R., Bordoloi, Devivasha, Cassel, Joel, Tursi, Nicholas J., Gary, Ebony, Weiner, David B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418050/ https://www.ncbi.nlm.nih.gov/pubmed/36090479 http://dx.doi.org/10.1016/j.omto.2022.07.003 |
Ejemplares similares
-
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape
por: Park, Daniel H., et al.
Publicado: (2023) -
A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy
por: Bordoloi, Devivasha, et al.
Publicado: (2022) -
Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers
por: Bordoloi, Devivasha, et al.
Publicado: (2023) -
DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas
por: Zhu, Xizhou, et al.
Publicado: (2021) -
For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
por: Singh, Kirit, et al.
Publicado: (2021)